Accéder au contenu
Merck

Examining the Impact of Galectin-9 on Latent HIV Transcription.

Methods in molecular biology (Clifton, N.J.) (2022-03-24)
Opeyemi S Adeniji, Leila B Giron, Mohamed Abdel-Mohsen
RÉSUMÉ

The β-galactoside-binding protein Galectin-9 (Gal-9) functions as a double-edged sword during HIV infection. On the one hand, Gal-9 can reactivate HIV latently infected cells, the main barrier to achieving HIV eradication, making them visible to immune clearance. On the other hand, Gal-9 induces latent HIV transcription by activating T cell Receptor (TCR) signaling pathways. These signaling pathways induce undesirable pro-inflammatory responses. While these unwanted responses can be mitigated by rapamycin without impacting Gal-9-mediated latent HIV reactivation, this effect raises the concern that Gal-9 may play a role in the chronic immune activation/inflammation that persists in people living with HIV despite antiretroviral therapy. Together, these data highlight the need to understand the positive and negative impacts of galectin interactions on immunological functions during HIV infection. In this chapter, we describe methods that can be used to investigate the effects of galectins, in particular Gal-9, on latent HIV transcription in vitro and ex vivo.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Phorbol 12-myristate 13-acétate, ≥99% (TLC), film or powder
Sigma-Aldrich
Rapamycin, Ready Made Solution, 2.5 mg/mL in DMSO (2.74 mM), from Streptomyces hygroscopicus